RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer(2023)

引用 4|浏览43
暂无评分
摘要
Patients with RET+ NSCLC have mainly thoracic and bone disease and low tumor mutational burden and programmed death-ligand 1 expression. RETi markedly improved survival, whereas ICB may be active in selected patients.
更多
查看译文
关键词
Chemotherapy,Immunotherapy,Non–small cell lung cancer,RET fusion,RET inhibitors
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络